Focal collaborates on restenosis treatments
This article was originally published in Clinica
Ciba Pharmaceuticals and Chiron will receive exclusive rights in selected restenosis fields to Focal's drug delivery technology under a collaborative agreement. The two drug companies will individually develop and market the final products, while Focal will retain manufacturing rights. Joint funding for certain preclinical studies will be provided by Ciba and Chiron, which will each fund development of its own products thereafter. Focal will receive royalties on product sales.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.